Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Hormonal Therapy

7 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    Breast

    VICCBRE1732

    04/04/2018

    PELOPS: Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study: A Randomized Phase II Study of Palbociclib with Endocrine Therapy versus Endocrine Therapy Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

    Treatment

    Breast

    VICCBRE16126

    08/10/2017

    PHIb Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (MBC)

    Treatment

    Breast

    VICCBRE15147

    01/20/2017

    A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial)

    Treatment

    Breast

    VICCBRE1640

    11/10/2016

    PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Treatment

    Prostate

    NRGUROR0924

    03/10/2016

    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    Prostate

    CTSUUROC90203-M

    11/05/2007

    A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer


    Print this page for your doctor